3M’s rumored divestiture of most of its drug-delivery business became a reality on 12 December, but the haul was far less than the one billion dollars that Bloomberg put out there earlier in the week.
The St. Paul, MN–based conglomerate entered into an agreement to sell substantially all of its drug-delivery business to an affiliate of Altaris Capital Partners LLC (New York) for approximately $650 million in total consideration, including cash, an interest-bearing security and a 17% non-controlling interest in the new company.
The 3M business is a global leader in drug delivery that partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using inhalation, transdermal, micro-needle and conventional drug-delivery technologies. 3M will retain its transdermal drug delivery components business. The business that is being divested has annual global sales of approximately $380 million.
“The drug delivery business is a leading provider of transdermal and inhalation delivery technologies,” said Michael Roman, 3M Chairman and CEO in a prepared statement. “This transaction will allow us to focus more resources on our core healthcare business as well as retain a share in the value of the drug-delivery business as it grows over the coming years.”
Buying and selling companies is more or less a core business activity of companies organized like 3M, writes Lee Schafer in the Minneapolis-based Star Tribune. In October, 3M paid approximately $6.7 billion, including assumption of debt, to acquire Acelity, which specializes in advanced wound-care and surgical products under the KCI brand. Although 3M has taken a hit on the stock market this year, declining about 19%, according to Bloomberg, the $33 billion company doesn’t need the money from the sale, writes Schafer. “It had $1.7 billion of free cash flow just in its most recent full quarter.”
So why sell a business that is a solid performer? “It could be as simple as it’s worth more to somebody else,” opines Shafer. “The buyer gets a business that’s worth more to them. The seller gets to take the money from the sale and invest it in opportunities that generate higher returns,” he writes. The proverbial win-win.
The transaction is subject to customary closing conditions and regulatory approvals. 3M said that it expects to close on the deal in the first half of 2020.
By Norbert Sparrow
Source: Plastics Today
BASF will build a commercial scale battery recycling black mass plant in Schwarzheide, Germany. This investment strengthens BASF’s cathode active materials (CAM) production and recycling hub in Schwarzheide. The site is an ideal location for the build-up of battery recycling activities given the presence of many EV car manufacturers and cell producers in Central Europe.
Clariant says it is reducing its number of businesses from five to three, by merging units, under a reorganization that is in line with the company’s purpose-led strategy and cultural transformation. The moves will position Clariant for long-term sustainable growth, the company says.
Chemicals & plastics industry has the most diversified end-use market across all manufacturing industries. The industry returned to growth in 2021 but a supply chain crunch prevented it from becoming stronger. The market is likely to stabilize in the second half of 2022 with a supply-demand balance.